SELL YOUR PRODUCTS
*mymedicalexpo  
English
video corpo

COVID-19 assay kit Lumipulse® G SARS-CoV-2 Ag
SARS-COV-2for antigensnasopharyngeal

COVID-19 assay kit
COVID-19 assay kit
Add to favorites
Compare this product
 

Characteristics

Applications
COVID-19
Tested parameter
SARS-COV-2, for antigens
Sample type
nasopharyngeal, saliva
Analysis mode
chemiluminescence, CLEIA

Description

For in vitro diagnostic (IVD) use with the Lumipulse G system for detection and quantitative measurement of SARS-CoV-2 nucleocapsid protein antigen in human nasopharyngeal swab or saliva. As a diagnostic tool for the confirmation of a SARS-CoV-2 infection. The assay utilises proven CLEIA (chemiluminescent enzyme immunoassay) technology with results that are available in up to 35 minutes. Please note that Lumipulse G assay need to be performed on either our LUMIPULSE G600II or LUMIPULSE G1200 in a clinical laboratory. CE marked Lumipulse® G SARS-CoV-2 Ag Immunoreaction Cartridges Product number 260340 3 x 14 Tests Lumipulse® G SARS-CoV-2 Ag Calibrators Product number 231869 4 x 4 Concentrations About SARS-CoV-2 The 2019 novel coronavirus infection disease (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1,2 In December 2019, the Health Commission of the City of Wuhan, Hubei Province, China, reported multiple pneumonia patients with unknown cause. On January 7th 2020, the World Health Organization (WHO) announced that the National Health Commission of China identified a new type of coronavirus, SARS-CoV-2.3 The WHO declared a COVID-19 pandemic on March 11th 2020 due to the worldwide spread of novel coronavirus infection.4
*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.